Literature DB >> 26168101

Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.

Andrew J Coldman1, Norm Phillips1, Dirk van Niekerk2, Laurie Smith1, Mel Krajden3, Darrel Cook1, David J Quinlan4, Thomas Ehlen4, Dianne Miller4, Gavin C E Stuart4, Stuart Peacock5, Ruth Elwood Martin6, Eduardo L Franco7, Gina Ogilvie3.   

Abstract

OBJECTIVE: To estimate the impact of implementing primary human papilloma virus liquid-based cytology (LBC) screening on four-year rates of referral for colposcopy in the British Columbia screening program.
METHODS: We used data on referral for colposcopy from an RCT (HPV FOCAL) comparing HPV testing every four years with LBC testing every two years. We also used data from population screening with conventional cytology among women aged 25 to 69. The predicted effect of adoption of either trial protocol on rates of referral for colposcopy was estimated using trial age-specific result and screening result-specific rates weighted by their screening program distribution. The cumulative age-specific rates of referral for colposcopy over four years were calculated.
RESULTS: Use of HPV testing initially increased rates of referral for colposcopy in the trial, but over four years the cumulative rates of referral were similar to those for LBC except in women aged 25 to 29, in whom a substantial excess persisted. Four-year rates of referral for colposcopy declined with age in women screened with HPV testing, LBC, and conventional cytology. Extrapolating the trial results to the distribution in the provincial screening program, implementation of either HPV or LBC throughout the provincial population would approximately double the current rates of referral for colposcopy.
CONCLUSION: Compared with LBC screening, primary screening for HPV increased rates of referral for colposcopy only among women aged 25 to 29. In contrast to current practice, referral for colposcopy was largely driven by the trial protocol recommendations for the management of abnormal results and not by which screening test was used.

Entities:  

Keywords:  HPV; cervical cancer screening; colposcopy

Mesh:

Year:  2015        PMID: 26168101     DOI: 10.1016/S1701-2163(15)30255-3

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  5 in total

1.  Implementation considerations using HPV self-collection to reach women under-screened for cervical cancer in high-income settings.

Authors:  H N Pedersen; L W Smith; C Sarai Racey; D Cook; M Krajden; D van Niekerk; G S Ogilvie
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

2.  Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

Authors:  C Popadiuk; C L Gauvreau; M Bhavsar; C Nadeau; K Asakawa; W M Flanagan; M C Wolfson; A J Coldman; S Memon; N Fitzgerald; J Lacombe; A B Miller
Journal:  Curr Oncol       Date:  2016-02-29       Impact factor: 3.677

3.  Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial.

Authors:  Andrew J Coldman; Lovedeep Gondara; Laurie W Smith; Dirk van Niekerk; Kathy Ceballos; Mel Krajden; Darrel Cook; David J Quinlan; Marette Lee; Gavin Ce Stuart; Stuart Peacock; Ruth Elwood Martin; Laura Gentile; Eduardo L Franco; Gina S Ogilvie
Journal:  Br J Cancer       Date:  2016-11-17       Impact factor: 7.640

4.  Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.

Authors:  Emily A Burger; Kine Pedersen; Stephen Sy; Ivar Sønbø Kristiansen; Jane J Kim
Journal:  Br J Cancer       Date:  2017-08-03       Impact factor: 7.640

5.  Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial.

Authors:  Anna Gottschlich; Lovedeep Gondara; Laurie W Smith; Darrel Cook; Ruth Elwood Martin; Marette Lee; Stuart Peacock; Lily Proctor; Gavin Stuart; Mel Krajden; Eduardo L Franco; Dirk van Niekerk; Gina Ogilvie
Journal:  Int J Cancer       Date:  2022-05-10       Impact factor: 7.316

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.